Enterprise Development Holdings' Subsidiary Invests RMB120 Million in Hainan Yayi Partnership

Reuters

Jul 10

Enterprise Development Holdings' Subsidiary Invests RMB120 Million in Hainan Yayi Partnership

Enterprise Development Holdings Limited, through its indirect wholly-owned subsidiary, has taken a significant step in the biomedical industry by acting as the sole managing partner of Qitong Fuyuan. The subsidiary has invested RMB120 million in Hainan Yayi Partnership, which recently acquired a 14.16% equity interest in the biomedicine-focused company 赛隆药业集团股份有限公司. This acquisition, valued at RMB199 million, marks a strategic move for Enterprise Development Holdings Limited in expanding its presence in the medical research and development sector. The transaction involved the company's participation in investment activities and asset management services within the biomedical field, particularly excluding human stem cells and gene diagnosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enterprise Development Holdings Limited published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2550623279"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550623279\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550623279?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-10 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550623279","market":"nz","top_or_hot":-1,"title":"Enterprise Development Holdings' Subsidiary Invests RMB120 Million in Hainan Yayi Partnership","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enterprise Development Holdings' Subsidiary Invests RMB120 Million in Hainan Yayi Partnership\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enterprise Development Holdings Limited, through its indirect wholly-owned subsidiary, has taken a significant step in the biomedical industry by acting as the sole managing partner of Qitong Fuyuan. The subsidiary has invested RMB120 million in Hainan Yayi Partnership, which recently acquired a 14.16% equity interest in the biomedicine-focused company 赛隆药业集团股份有限公司. This acquisition, valued at RMB199 million, marks a strategic move for Enterprise Development Holdings Limited in expanding its presence in the medical research and development sector. The transaction involved the company's participation in investment activities and asset management services within the biomedical field, particularly excluding human stem cells and gene diagnosis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enterprise Development Holdings Limited published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enterprise Development Holdings' Subsidiary Invests RMB120 Million in Hainan Yayi Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnterprise Development Holdings' Subsidiary Invests RMB120 Million in Hainan Yayi Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-10 21:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enterprise Development Holdings' Subsidiary Invests RMB120 Million in Hainan Yayi Partnership\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enterprise Development Holdings Limited, through its indirect wholly-owned subsidiary, has taken a significant step in the biomedical industry by acting as the sole managing partner of Qitong Fuyuan. The subsidiary has invested RMB120 million in Hainan Yayi Partnership, which recently acquired a 14.16% equity interest in the biomedicine-focused company 赛隆药业集团股份有限公司. This acquisition, valued at RMB199 million, marks a strategic move for Enterprise Development Holdings Limited in expanding its presence in the medical research and development sector. The transaction involved the company's participation in investment activities and asset management services within the biomedical field, particularly excluding human stem cells and gene diagnosis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enterprise Development Holdings Limited published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1117","symbol_name":"系统软件","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nNDL9RfnmG:1","article_id":"2550623279","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550623279","pubTimestamp":1752153577,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Enterprise Development Holdings Limited, through its indirect wholly-owned subsidiary, has taken a significant step in the biomedical industry by acting as the sole managing partner of Qitong Fuyuan. The subsidiary has invested RMB120 million in Hainan Yayi Partnership, which recently acquired a 14.16% equity interest in the biomedicine-focused company 赛隆药业集团股份有限公司. This acquisition, valued at RMB199 million, marks a strategic move for Enterprise Development Holdings Limited in expanding its presence in the medical research and development sector. The transaction involved the company's participation in investment activities and asset management services within the biomedical field, particularly excluding human stem cells and gene diagnosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1117":"系统软件","01808":"企展控股"},"translate_title":"Enterprise Development Holdings' Subsidiary Investments RMB120 Million in Hainan Yayi Partnership","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01808":0.9},"content_text":"Enterprise Development Holdings' Subsidiary Invests RMB120 Million in Hainan Yayi Partnership\n    \n\n        Enterprise Development Holdings Limited, through its indirect wholly-owned subsidiary, has taken a significant step in the biomedical industry by acting as the sole managing partner of Qitong Fuyuan. The subsidiary has invested RMB120 million in Hainan Yayi Partnership, which recently acquired a 14.16% equity interest in the biomedicine-focused company 赛隆药业集团股份有限公司. This acquisition, valued at RMB199 million, marks a strategic move for Enterprise Development Holdings Limited in expanding its presence in the medical research and development sector. The transaction involved the company's participation in investment activities and asset management services within the biomedical field, particularly excluding human stem cells and gene diagnosis.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enterprise Development Holdings Limited published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}